Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)--Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today ...
Bulk harvest release testing for adventitious viruses is an integral part of biosafety for manufacturing biopharma products. Finding a testing strategy that works for diverse biologics modalities ...
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to improve the detection and diagnosis of rare genetic diseases. The core ...
The company that created the first genome sequencing test for IVF embryo screening has partnered with the world’s leading polygenic embryo testing company to launch the most significant advance in IVF ...
Next-generation sequencing (NGS) is recommended for patients with metastatic prostate cancer (PC). Nationwide, testing rates are low. Whether PC disease characteristics and courses differ between ...
Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...
The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
For more than four decades, in vitro fertilization (IVF) has helped families have children. Scientists estimate that more than 10 million people worldwide have been born through IVF and related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results